Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 329481, 10 pages
http://dx.doi.org/10.1155/2015/329481
Review Article

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives

1Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, 69126 Heidelberg, Germany
2Translational Lung Research Center Heidelberg (TLRCH), Member of the German Center for Lung Research (DZL), 69126 Heidelberg, Germany
3Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, 45141 Essen, Germany
4Department of Pulmonary Disease, Erasmus Medical Centre, University Hospital Rotterdam, 3015 CE Rotterdam, Netherlands
5National Institute for Health Research Biological Research Unit, Royal Brompton Hospital, London SW3 6NP, UK
6National Heart and Lung Institute, Imperial College, London SW3 6NP, UK
7Medical University Clinic, Canton Hospital Baselland and University of Basel, 4410 Liestal, Switzerland

Received 4 September 2015; Accepted 11 November 2015

Academic Editor: Natale Daniele Brunetti

Copyright © 2015 Michael Kreuter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Raghu, H. R. Collard, J. J. Egan et al., “An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 788–824, 2011. View at Publisher · View at Google Scholar
  2. P. Spagnolo, N. Sverzellati, G. Rossi et al., “Idiopathic pulmonary fibrosis: an update,” Annals of Medicine, vol. 47, no. 1, pp. 15–27, 2015. View at Publisher · View at Google Scholar
  3. G. Raghu, D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster, “Incidence and prevalence of idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 810–816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Raghu, S.-Y. Chen, W.-S. Yeh et al., “Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11,” The Lancet Respiratory Medicine, vol. 2, no. 7, pp. 566–572, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Hutchinson, A. Fogarty, R. Hubbard, and T. McKeever, “Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review,” The European Respiratory Journal, vol. 46, no. 3, pp. 795–806, 2015. View at Publisher · View at Google Scholar
  6. GBD 2013 Mortality and Causes of Death Collaborators, “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 385, pp. 117–171, 2015. View at Google Scholar
  7. K. Iwai, T. Mori, N. Yamada, M. Yamaguchi, and Y. Hosoda, “Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure,” American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 3, pp. 670–675, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. A. L. Olson and J. J. Swigris, “Idiopathic pulmonary fibrosis: diagnosis and epidemiology,” Clinics in Chest Medicine, vol. 33, no. 1, pp. 41–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Spagnolo, J. Grunewald, and R. M. du Bois, “Genetic determinants of pulmonary fibrosis: evolving concepts,” The Lancet Respiratory Medicine, vol. 2, no. 5, pp. 416–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Bjoraker, J. H. Ryu, M. K. Edwin et al., “Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 1, pp. 199–203, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. K. R. Flaherty, G. B. Toews, W. D. Travis et al., “Clinical significance of histological classification of idiopathic interstitial pneumonia,” European Respiratory Journal, vol. 19, no. 2, pp. 275–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Behr, M. M. Hoeper, M. Kreuter, J. Klotsche, H. Wirtz, and D. Pittrow, “Characteristics and management of idiopathic pulmonary fibrosis: the INSIGHTS-IPF registry,” Deutsche Medizinische Wochenschrift, vol. 137, no. 49, pp. 2586–2588, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. E. King Jr., M. I. Schwarz, K. Brown et al., “Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 6, pp. 1025–1032, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Ley, H. R. Collard, and T. E. King Jr., “Clinical course and prediction of survival in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 4, pp. 431–440, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. American Thoracic Society (ATS) and European Respiratory Society (ERS), “Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 2, pp. 646–664, 2000. View at Publisher · View at Google Scholar
  16. M. Selman and A. Pardo, “Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model,” American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 10, pp. 1161–1172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Spagnolo, G. Rossi, and A. Cavazza, “Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications,” Expert Review of Clinical Immunology, vol. 10, no. 8, pp. 1005–1017, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. T. E. King Jr., W. Z. Bradford, S. Castro-Bernardini et al., “A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2083–2092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Richeldi, R. M. Du Bois, G. Raghu et al., “Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2071–2082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Kreuter, “Pirfenidone: an update on clinical trial data and insights from everyday practice,” European Respiratory Review, vol. 23, no. 131, pp. 111–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Idiopathic Pulmonary Fibrosis Clinical Research Network, F. J. Martinez, J. A. de Andrade, K. J. Anstrom, T. E. King Jr., and G. Raghu, “Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis,” The New England Journal of Medicine, vol. 366, pp. 1968–1977, 2012. View at Google Scholar
  22. I. Noth, K. J. Anstrom, S. B. Calvert et al., “A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 1, pp. 88–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Raghu, B. Rochwerg, Y. Zhang et al., “An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline,” American Journal of Respiratory and Critical Care Medicine, vol. 192, no. 2, pp. e3–e19, 2015. View at Publisher · View at Google Scholar
  24. S. N. Iyer, G. Gurujeyalakshmi, and S. N. Giri, “Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 1, pp. 367–373, 1999. View at Google Scholar · View at Scopus
  25. H. Oku, T. Shimizu, T. Kawabata et al., “Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis,” European Journal of Pharmacology, vol. 590, no. 1–3, pp. 400–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Taniguchi, M. Ebina, Y. Kondoh et al., “Pirfenidone in idiopathic pulmonary fibrosis,” The European Respiratory Journal, vol. 35, no. 4, pp. 821–829, 2010. View at Publisher · View at Google Scholar
  27. P. W. Noble, C. Albera, W. Z. Bradford et al., “Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials,” The Lancet, vol. 377, no. 9779, pp. 1760–1769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Spagnolo, C. Del Giovane, F. Luppi et al., “Non-steroid agents for idiopathic pulmonary fibrosis,” Cochrane Database of Systematic Reviews, no. 9, Article ID CD003134, 2010. View at Google Scholar · View at Scopus
  29. U. Costabel, E. Bendstrup, V. Cottin et al., “Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events,” Advances in Therapy, vol. 31, pp. 375–391, 2014, Erratum in Advances in Therapy, vol. 31, no. 5, pp. 575-576, 2014. View at Google Scholar
  30. G. M. Keating, “Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis,” Drugs, vol. 75, no. 10, pp. 1131–1140, 2015. View at Publisher · View at Google Scholar
  31. N. Ahluwalia, B. S. Shea, and A. M. Tager, “New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses,” American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 8, pp. 867–878, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Richeldi, V. Cottin, K. R. Flaherty et al., “Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis,” Respiratory Medicine, vol. 108, no. 7, pp. 1023–1030, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Raghu, T. D. Freudenberger, S. Yang et al., “High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 27, no. 1, pp. 136–142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. S. Lee, J. H. Ryu, B. M. Elicker et al., “Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 12, pp. 1390–1394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. S. Lee, H. R. Collard, K. J. Anstrom et al., “Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials,” The Lancet Respiratory Medicine, vol. 1, no. 5, pp. 369–376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Galiè, M. Humbert, J. L. Vachiery et al., “ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT),” European Respiratory Journal, vol. 46, no. 5, pp. 903–975, 2015. View at Publisher · View at Google Scholar
  37. H. R. Collard, K. J. Anstrom, M. I. Schwarz, and D. A. Zisman, “Sildenafil improves walk distance in idiopathic pulmonary fibrosis,” Chest, vol. 131, no. 3, pp. 897–899, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. Idiopathic Pulmonary Fibrosis Clinical Research Network, D. A. Zisman, M. Schwarz et al., “A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 363, no. 7, pp. 620–628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. M. K. Han, D. S. Bach, P. G. Hagan et al., “Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction,” Chest, vol. 143, no. 6, pp. 1699–1708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. T. E. King Jr., J. Behr, K. K. Brown et al., “BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 1, pp. 75–81, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. T. E. King Jr., K. K. Brown, G. Raghu et al., “BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 92–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Raghu, R. Million-Rousseau, A. Morganti, L. Perchenet, J. Behr, and MUSIC Study Group, “Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial,” European Respiratory Journal, vol. 42, no. 6, pp. 1622–1632, 2013. View at Publisher · View at Google Scholar
  43. A. M. Cantin, R. C. Hubbard, and R. G. Crystal, “Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis,” American Review of Respiratory Disease, vol. 139, no. 2, pp. 370–372, 1989. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Tomioka, Y. Kuwata, K. Imanaka et al., “A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis,” Respirology, vol. 10, no. 4, pp. 449–455, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Homma, A. Azuma, H. Taniguchi et al., “Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis,” Respirology, vol. 17, no. 3, pp. 467–477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. Idiopathic Pulmonary Fibrosis Clinical Research Network, F. J. Martinez, J. A. de Andrade, K. J. Anstrom, T. E. King Jr., and G. Raghu, “Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis,” The New England Journal of Medicine, vol. 370, no. 22, pp. 2093–2101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Oldham, S.-F. Ma, F. J. Martinez et al., “TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, 2015. View at Publisher · View at Google Scholar
  48. C. S. King and S. D. Nathan, “Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis,” Current Opinion in Pulmonary Medicine, vol. 21, pp. 479–489, 2015. View at Google Scholar
  49. P. Spagnolo, R. M. du Bois, and V. Cottin, “Rare lung disease and orphan drug development,” The Lancet Respiratory Medicine, vol. 1, no. 6, pp. 479–487, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Spagnolo, A. U. Wells, and H. R. Collard, “Pharmacological treatment of idiopathic pulmonary fibrosis: an update,” Drug Discovery Today, vol. 20, pp. 514–524, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. J. M. Harris, I. D. A. Johnston, R. Rudd, A. J. Newman Taylor, and P. Cullinan, “Cryptogenic fibrosing alveolitis and lung cancer: the BTS study,” Thorax, vol. 65, no. 1, pp. 70–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Ozawa, T. Suda, T. Naito et al., “Cumulative incidence of and predictive factors for lung cancer in IPF,” Respirology, vol. 14, no. 5, pp. 723–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. C. E. Daniels and J. R. Jett, “Does interstitial lung disease predispose to lung cancer?” Current Opinion in Pulmonary Medicine, vol. 11, no. 5, pp. 431–437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. M.-C. Aubry, J. L. Myers, W. W. Douglas et al., “Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis,” Mayo Clinic Proceedings, vol. 77, no. 8, pp. 763–770, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. R. J. Panos, R. L. Mortenson, S. A. Niccoli, and T. E. King Jr., “Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment,” The American Journal of Medicine, vol. 88, no. 4, pp. 396–404, 1990. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Kreuter, S. Ehlers-Tenenbaum, M. Schaaf et al., “Treatment and outcome of lung cancer in idiopathic interstitial pneumonias,” Sarcoidosis Vasculitis and Diffuse Lung Diseases, vol. 31, no. 4, pp. 266–274, 2015. View at Google Scholar · View at Scopus
  57. S. Tomassetti, C. Gurioli, J. H. Ryu et al., “The impact of lung cancer on survival of idiopathic pulmonary fibrosis,” Chest, vol. 147, no. 1, pp. 157–164, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. C. D. Fell, “Idiopathic pulmonary fibrosis: phenotypes and comorbidities,” Clinics in Chest Medicine, vol. 33, no. 1, pp. 51–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. K. C. Meyer, S. K. Danoff, L. H. Lancaster, and S. D. Nathan, “Management of idiopathic pulmonary fibrosis in the elderly patient,” CHEST Journal, vol. 148, no. 1, pp. 242–452, 2015. View at Publisher · View at Google Scholar
  60. R. M. du Bois, D. Weycker, C. Albera et al., “Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 9, pp. 1231–1237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. R. M. du Bois, C. Albera, W. Z. Bradford et al., “6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 43, no. 5, pp. 1421–1429, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. P. W. Noble, C. Albera, W. Z. Bradford et al., “Analysis of pooled data from 3 phase 3, multinational, randomized, double-blind, placebo controlled trials evaluating pirfenidone in patients with idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 189, Article ID A1423, 2014. View at Google Scholar
  63. W. A. Wuyts, K. M. Antoniou, K. Borensztajn et al., “Combination therapy: the future of management for idiopathic pulmonary fibrosis?” The Lancet Respiratory Medicine, vol. 2, no. 11, pp. 933–942, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Ogura, H. Taniguchi, A. Azuma et al., “Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis,” European Respiratory Journal, vol. 45, no. 5, pp. 1382–1392, 2015. View at Publisher · View at Google Scholar
  65. T. M. Maher, “Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine,” Current Opinion in Pulmonary Medicine, vol. 19, no. 5, pp. 460–465, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Spagnolo, A. Tzouvelekis, and T. M. Maher, “Personalized medicine in idiopathic pulmonary fibrosis: facts and promises,” Current Opinion in Pulmonary Medicine, vol. 21, no. 5, pp. 470–478, 2015. View at Publisher · View at Google Scholar
  67. C. D. Fell, F. J. Martinez, L. X. Liu et al., “Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 8, pp. 832–837, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Novelli, L. Tavanti, S. Cini et al., “Determinants of the prognosis of idiopathic pulmonary fibrosis,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 6, pp. 880–886, 2014. View at Google Scholar · View at Scopus
  69. H. Sumikawa, T. Johkoh, K. Fujimoto et al., “Pathologically proved nonspecific interstitial pneumonia: CT pattern analysis as compared with usual interstitial pneumonia CT Pattern,” Radiology, vol. 272, no. 2, pp. 549–556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. A. S. Chang, J. Munson, A. H. Gifford, and D. A. Mahler, “Prospective use of descriptors of dyspnea to diagnose common respiratory diseases,” CHEST Journal, vol. 148, no. 4, pp. 895–902, 2015. View at Publisher · View at Google Scholar
  71. G. Raghu, D. Lynch, J. D. Godwin et al., “Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial,” The Lancet Respiratory Medicine, vol. 2, no. 4, pp. 277–284, 2014. View at Publisher · View at Google Scholar · View at Scopus